"Non targeted analysis" trang 1 - tải miễn phí từ tailieunhanh
Compound specific isotope analysis (CSIA) of phthalates and non-targeted isotope analysis (NTIA) of SPE-extractable organic carbon in dilute aquatic environments

Compound specific isotope analysis (CSIA) of phthalates and non-targeted isotope analysis (NTIA) of SPE-extractable organic carbon in dilute aquatic environments
8    56    3
MetICA: Independent component analysis for high-resolution mass-spectrometry based non-targeted metabolomics

MetICA: Independent component analysis for high-resolution mass-spectrometry based non-targeted metabolomics
14    48    1
Non-targeted Gas Chromatography Orbitrap Mass Spectrometry qualitative and quantitative analysis of semi-volatile organic compounds in indoor dust using the Regions of Interest Multivariate Curve Resolution chemometrics procedure

Non-targeted Gas Chromatography Orbitrap Mass Spectrometry qualitative and quantitative analysis of semi-volatile organic compounds in indoor dust using the Regions of Interest Multivariate Curve Resolution chemometrics procedure
23    24    1
Gefitinib provides similar effectiveness and improved safety than erlotinib for east Asian populations with advanced non–small cell lung cancer: A meta-analysis

Gefitinib provides similar effectiveness and improved safety than erlotinib for east Asian populations with advanced non–small cell lung cancer: A meta-analysis
14    81    0
A systematic review of the cost-effectiveness of targeted therapies for metastatic non-small cell lung cancer (NSCLC)

A systematic review of the cost-effectiveness of targeted therapies for metastatic non-small cell lung cancer (NSCLC)
11    26    1
Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced nonsmall cell lung cancer: A meta-analysis

Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced nonsmall cell lung cancer: A meta-analysis
16    106    0
Comparative survival benefit of currently licensed second or third line treatments for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) negative advanced or metastatic non-small cell lung cancer: A systematic review and secondary analysis of trials

Comparative survival benefit of currently licensed second or third line treatments for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) negative advanced or metastatic non-small cell lung cancer: A systematic review and secondary analysis of trials
17    86    0
Network-based differential gene expression analysis suggests cell cycle related genes regulated by E2F1 underlie the molecular difference between smoker and non-smoker lung adenocarcinoma

Network-based differential gene expression analysis suggests cell cycle related genes regulated by E2F1 underlie the molecular difference between smoker and non-smoker lung adenocarcinoma
16    39    1
Feasibility of tissue re-biopsy in non-small cell lung cancers resistant to previous epidermal growth factor receptor tyrosine kinase inhibitor therapies

Feasibility of tissue re-biopsy in non-small cell lung cancers resistant to previous epidermal growth factor receptor tyrosine kinase inhibitor therapies
9    44    1
Second dimension retention indices in “normal” orthogonality comprehensive two-dimensional gas chromatography using single standard injection generated isovolatility curves

Second dimension retention indices in “normal” orthogonality comprehensive two-dimensional gas chromatography using single standard injection generated isovolatility curves
5    12    1
A non-targeted metabolomic approach to identify food markers to support discrimination between organic and conventional tomato crops

A non-targeted metabolomic approach to identify food markers to support discrimination between organic and conventional tomato crops
11    15    1
Validating ORR and PFS as surrogate endpoints in phase II and III clinical trials for NSCLC patients: Difference exists in the strength of surrogacy in various trial settings

Validating ORR and PFS as surrogate endpoints in phase II and III clinical trials for NSCLC patients: Difference exists in the strength of surrogacy in various trial settings
13    1    1
Non-targeted metabolite profiling of citrus juices as a tool for variety discrimination and metabolite flow analysis

Non-targeted metabolite profiling of citrus juices as a tool for variety discrimination and metabolite flow analysis
16    75    0